EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

Amélie Giguère, Isabelle Raymond-Bouchard iD, Vanessa Collin, Jean-Sébastien Claveau, Josée Hébert iD, Richard LeBlanc

Cancers · 22.09.2023 · 15 (19) · 4687

DOI: 10.3390/cancers15194687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 22.09.2023. Verfasst von Amélie Giguère und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canada Research Chairs, Fonds de Recherche du Québec - Santé, Université de Montréal at Hôpital Maisonneuve-Rosemont.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fluorescence in situ hybridization (FISH) on enriched CD138 plasma cells is the standard method for identification of clinically relevant genetic abnormalities in multiple myeloma. However, FISH is a targeted analysis that can be challenging due to the genetic complexity of myeloma. The aim of this study was to evaluate the potential of optical genome mapping (OGM) to detect clinically significant cytogenetic abnormalities in myeloma and to provide larger pangenomic information. OGM and FISH analyses were performed on CD138-purified cells of 20 myeloma patients. OGM successfully detected structural variants (SVs) (IGH and MYC rearrangements), copy number variants (CNVs) (17p/TP53 deletion, 1p deletion and 1q gain/amplification) and aneuploidy (gains of odd-numbered chromosomes, monosomy 13) classically expected with myeloma and led to a 30% increase in prognosis yield at our institution when compared to FISH. Despite challenges in the interpretation of OGM calls for CNV and aneuploidy losses in non-diploid genomes, OGM has the potential to replace FISH as the standard of care analysis in clinical settings and to efficiently change how we identify prognostic and predictive markers for therapies in the future. To our knowledge, this is the first study highlighting the feasibility and clinical utility of OGM in myeloma.

Schlagwörter

Stichwörter der Autor:innen

1p deletion1q gain/amplificationIGH translocationsPVT1 rearrangementcytogeneticshyperdiploidymyelomaoptical genome mapping

Autor:innen und Institutionen

  • Cytogenetics Laboratory, Maisonneuve-Rosemont Hospital, Montreal, QC H1T 2M4, Canada.
  • Division of Hematology, Oncology and Transplantation, Department of Medicine, Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, QC H1T 2M4, Canada.

ORCID-Profile: Isabelle Raymond-Bouchard, Josée Hébert

Förderung

  • Canada Research Chairs
  • Fonds de Recherche du Québec - Santé
  • Université de Montréal at Hôpital Maisonneuve-Rosemont
  • Fonds de recherche du Québec–Santé

Zitieren

APA

Giguère, A., Raymond-Bouchard, I., Collin, V., Claveau, J. S., Hébert, J., & LeBlanc, R. (2023). Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Cancers, 15(19), 4687. https://doi.org/10.3390/cancers15194687

Vancouver

Giguère A, Raymond-Bouchard I, Collin V, Claveau JS, Hébert J, LeBlanc R. Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma. Cancers. 2023;15(19):4687. doi:10.3390/cancers15194687

BibTeX
@article{Gigure2023,
  author = {Giguère, Amélie and Raymond-Bouchard, Isabelle and Collin, Vanessa and Claveau, Jean-Sébastien and Hébert, Josée and LeBlanc, Richard},
  title = {Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {19},
  pages = {4687},
  doi = {10.3390/cancers15194687}
}
Kostenlos starten →